Trodelvy® Improved Progression-Free Survival by 34% in Heavily Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients

Press release content from Business Wire. The AP news staff was not involved in its creation.

Related Keywords

California ,United States ,University Of California San Francisco ,Foster City ,American ,Jacquie Ross ,Gilead Sciences ,American Society Of Clinical Oncology ,College Of American Pathologists ,Gilead Sciences Inc ,Nasdaq ,Exchange Commission ,Gilead Public Affairs ,Hope Rugo ,Breast Oncology ,Clinical Trials Education ,Bill Grossman ,Senior Vice President ,Therapeutic Area Head ,Boxed Warning ,Important Safety ,Response Evaluation Criteria ,Solid Tumors ,American Society ,Clinical Oncology ,American Pathologists ,Safety Information ,Withhold Trodelvy ,Infusion Related Reactions ,Adverse Reactions ,Fetal Toxicity ,Prescribing Information ,Private Securities Litigation Reform Act ,Quarterly Report ,Business Wire ,Politics ,Health ,Chemotherapy ,Cancer ,Breast Cancer ,